Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.14) per share for the quarter, up from their prior forecast of ($0.20). The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at $0.48 EPS, Q4 2025 earnings at $0.61 EPS and FY2026 earnings at $3.18 EPS.
Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th.
Check Out Our Latest Stock Analysis on FRX
Fennec Pharmaceuticals Stock Performance
Shares of TSE:FRX traded up C$0.36 on Thursday, hitting C$9.48. The company's stock had a trading volume of 207 shares, compared to its average volume of 1,501. The company has a market capitalization of C$182.82 million, a price-to-earnings ratio of -160.59 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$15.20. The stock's 50-day moving average is C$9.21 and its two-hundred day moving average is C$7.94.
Insider Transactions at Fennec Pharmaceuticals
In related news, Director Rostislav Christov Raykov bought 25,000 shares of Fennec Pharmaceuticals stock in a transaction dated Friday, December 20th. The stock was acquired at an average cost of C$3.87 per share, with a total value of C$96,840.00. In the last 90 days, insiders have sold 21,186 shares of company stock valued at $196,017. Corporate insiders own 16.20% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
